Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia
    Research/Science 3/28/2023

    At a glance
    In this general discussion post, the primary subjects mentioned are
    ๐Ÿ’ง pyrilutamide (topical) 24 weeks
    the tone is ๐Ÿ˜€ positive.

    Other terms

    Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.
    View this post in the Community โ†’

    Similar Community Posts Join

    5 / 182 results

    Related Research

    6 / 124 results